| 000 | 01319 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250515100514.0 | ||
| 264 | 0 | _c20080226 | |
| 008 | 200802s 0 0 eng d | ||
| 022 | _a0042-4900 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aClemente, M | |
| 245 | 0 | 0 |
_aComparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism. _h[electronic resource] |
| 260 |
_bThe Veterinary record _cDec 2007 |
||
| 300 |
_a805-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdrenocortical Hyperfunction _xdrug therapy |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Hormonal _xadverse effects |
| 650 | 0 | 4 |
_aBody Weight _xphysiology |
| 650 | 0 | 4 |
_aDihydrotestosterone _xadverse effects |
| 650 | 0 | 4 |
_aDog Diseases _xdrug therapy |
| 650 | 0 | 4 | _aDogs |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMitotane _xadverse effects |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aDe Andrés, P J | |
| 700 | 1 | _aArenas, C | |
| 700 | 1 | _aMelián, C | |
| 700 | 1 | _aMorales, M | |
| 700 | 1 | _aPérez-Alenza, M D | |
| 773 | 0 |
_tThe Veterinary record _gvol. 161 _gno. 24 _gp. 805-9 |
|
| 999 |
_c17596972 _d17596972 |
||